Crimi Ettore, Hernandez-Barajas Daniel, Seller Aaron, Ashton Jennifer, Martin Mark, Vasilopoulos Terrie, Gravenstein Nikolaus
University of Florida.
College of Medicine, University of Florida, 1600 SW Archer Road, PO Box 100254, Gainesville, FL 32610.
J Cardiothorac Vasc Anesth. 2019 Jan;33(1):102-106. doi: 10.1053/j.jvca.2018.06.004. Epub 2018 Jun 19.
The aim of this study was to investigate whether the use of modified ultrafiltration at the end of cardiopulmonary bypass for cardiac surgical procedures significantly changes vancomycin serum concentrations.
Prospective study.
Single tertiary cardiac center.
Twenty-six elective adult patients undergoing cardiac surgery with cardiopulmonary bypass from April 2014 to April 2015.
Serum vancomycin concentrations were measured just before cardiopulmonary bypass; during cardiopulmonary bypass at 5, 30, 60 minutes and then every 60 minutes; after completion of cardiopulmonary bypass before initiation of modified ultrafiltration; and at the end of modified ultrafiltration.
Seventeen patients received modified ultrafiltration at the end of cardiopulmonary bypass. Serum vancomycin concentrations prior to cardiopulmonary bypass (45.9 ± 17.3 μg/mL) were significantly higher (P < 0.0001) than each time point following cardiopulmonary bypass (5 min 20.4 ± 6.4 μg/mL, 30 min 18.8 ± 5.4 μg/mL, 60 min 16.6 ± 4.9 μg/mL, and 120 min 14.3 ± 4.7 μg/mL). In the modified ultrafiltration group, serum vancomycin concentrations were 14.7 ± 4.6 μg/mL prior to modified ultrafiltration and 13.9 ± 4.3 μg/mL after ultrafiltration; this difference was statistically significant (P = 0.0288). The mean modified ultrafiltration volume was 465 ± 158 mL.
Using modified ultrafiltration at the end of cardiopulmonary bypass significantly decreases serum vancomycin levels, but not by a clinically relevant amount. The decrease is to a concentration that is still significantly higher than the minimum inhibitory concentration for Staphylococcus epidermidis and Staphylococcus aureus; thus additional vancomycin administration is not recommended.
本研究旨在调查在心脏外科手术的体外循环结束时使用改良超滤是否会显著改变万古霉素的血清浓度。
前瞻性研究。
单一的三级心脏中心。
2014年4月至2015年4月期间接受体外循环心脏手术的26例择期成年患者。
在体外循环前、体外循环期间5分钟、30分钟、60分钟,然后每60分钟、体外循环结束后开始改良超滤前以及改良超滤结束时测量血清万古霉素浓度。
17例患者在体外循环结束时接受了改良超滤。体外循环前血清万古霉素浓度(45.9±17.3μg/mL)显著高于体外循环后的每个时间点(5分钟时20.4±6.4μg/mL,30分钟时18.8±5.4μg/mL,60分钟时16.6±4.9μg/mL,120分钟时14.3±4.7μg/mL)(P<0.0001)。在改良超滤组中,改良超滤前血清万古霉素浓度为14.7±4.6μg/mL,超滤后为13.9±4.3μg/mL;这种差异具有统计学意义(P = 0.0288)。改良超滤的平均体积为465±158mL。
在体外循环结束时使用改良超滤可显著降低血清万古霉素水平,但降低幅度在临床上无显著意义。降低后的浓度仍显著高于表皮葡萄球菌和金黄色葡萄球菌的最低抑菌浓度;因此不建议额外给予万古霉素。